Remedium Lifecare Limited (BSE: 539561) has announced the launch of its much-anticipated Rights Issue, which has received approval from the Bombay Stock Exchange (BSE). This strategic initiative marks a significant step in the company’s journey toward becoming a vertically integrated, research-driven pharmaceutical leader. The Rights Issue opens on April 30, 2025, and close on May 14, 2025. The capital raise comes on the heels of Remedium’s recent ₹182.7 crore agreement with a prominent UK-based pharmaceutical
company, underscoring its commitment to international expansion. The funds raised will be utilized to strengthen working capital, Investment in R&D capabilities, scale up the production of high-value pharmaceutical intermediates, attract top talent, drive digital transformation, and accelerate global market penetration.
Speaking on the development, Mr. Adarsh Munjal, Managing Director of Remedium Lifecare Limited, commented: “This Rights Issue represents a significant milestone in our journey to become a globally recognized, innovation-led pharmaceutical company. The capital infusion will strengthen our strategic partnerships across domestic and international markets, with a particular focus on Europe and Asia.” He also added that
“It offers an exciting opportunity for investors to subscribe to the offer within the specified period and enhance their stake in the company at a potentially attractive price.”